affiliate disclosure · we earn commission on some vendor links. audits, scores, and rankings are independent — vendors do not pay for placement. read more →
Peptide research & literature
Sara writes the peptide guides, the mechanism explainers, and the research-literature reviews. Her background is in pharmacology research — eight years at a contract research organization running preclinical pharmacokinetics work before moving into science writing full-time. She reads the primary research literature so vialaudit readers don't have to, and she's the person on the desk who decides which peptide is mature enough for a guide. If a compound only has rodent data, she says so. If a Phase 2 trial is being misrepresented in community discussion, she writes the literature read. Sara writes under a pen name. The peptide research-protocol space attracts strong opinions and direct outreach to authors; she'd rather keep the email volume manageable and the work honest.
Peptide guides, mechanism explainers, primary-literature reviews, pharmacokinetics summaries, dose-research literature, trial result reads.
No peptide is approved to treat insomnia. The best human sleep data belong to GHRH, the hormone sermorelin is cut from, which raised deep sleep in sleep-lab studies of 7 to 23 men. DSIP's best trial was negative. Ipamorelin, CJC-1295 and Selank have no sleep study at all.
A research read on the peptides currently studied for longevity outcomes - rapamycin, NAD+, MOTS-c, GHK-Cu, Klotho, epitalon, GHRH analogs, and the rest. Which have human evidence, which have only model-organism data, and what each actually does at the mechanism level.
KLOW is a four-component peptide stack growing fast in research-protocol discussion. Here's the literature read - what each compound does, what the mechanism overlap argues, and what's actually been studied as a combination.
The Wolverine stack is BPC-157 plus TB-500. No human trial has tested the pair. Of 81 blend lab results we checked, 1 failed on fill.
TRIUMPH-2 stepped retatrutide 2, 4, 6, 9, then 12 mg every 4 weeks. Week-by-week chart with syringe units for 10 and 20 mg vials.
Nausea hit 28% on 12 mg retatrutide vs 8% on placebo in TRIUMPH-2. Diarrhea, dysesthesia, hypotension and dropout rates by dose, from The Lancet.
All four retatrutide Phase 3 readouts on 12 mg: TRIUMPH-4 28.7% at 68 weeks (topline), TRIUMPH-1 25.0% (NEJM), TRIUMPH-2 18.8% (The Lancet), TRIUMPH-3 22.6% (topline).
Tips, corrections, or comments on research desk coverage: research@vialaudit.com